Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Cercek
Dr. Andrea Cercek is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from New York Medical College and has been in practice 13 years. She is one of 502 doctors at Memorial Sloan Kettering Cancer Center and one of 62 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2006 - 2026
CT State Medical License 2024 - 2025
NJ State Medical License 2020 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical and Translational Study of STA-9090 Start of enrollment: 2010 Apr 01
- A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours Start of enrollment: 2011 Jan 01
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Start of enrollment: 2013 Sep 05
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAdjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.Jeremy Sharib, Kristen E Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew
Annals of Surgical Oncology. 2025-04-01 - ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.Jeremy Sharib, Kristen E Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew
Annals of Surgical Oncology. 2025-04-01 - Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation.Nicole Aguirre, Darren R Veach, Andrea Cercek, Sarah M Cheal, Steven M Larson
Cell Reports. Medicine. 2025-03-24
Journal Articles
- Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—ReplyAndrea Cercek, MD, JAMA Oncology
- Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal DepositsJinru Shia, Garrett M Nash, Philip B Paty, Andrea Cercek, Campbell S Roxburgh, Annals of Surgical Oncology
- Pelvic MRI After Induction Chemotherapy and Before Long-Course Chemoradiation Therapy for Rectal Cancer: What Are the Imaging Findings?Andrea Cercek, Leonard Saltz, Marc J Gollub, Patricio Lynn, Martin R Weiser, European Radiology
- Join now to see all
Lectures
- Gastrointestinal (Colorectal) CancerASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Prevalence of germline genetic alterations in colorectal cancer patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—ReplyApril 2020
Press Mentions
Lifesaving Cancer Study Delivers Complete Remission for All Trial PatientsMarch 6th, 2025- FDA Approved Drug Achieves 100% Remission for Rectal CancerDecember 31st, 2024
- Groundbreaking Clinical Trial Cures Cancer in 100% of PatientsNovember 20th, 2024
- Join now to see all
Grant Support
- Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancerSLOAN-KETTERING INST CAN RESEARCH2022–2027
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
